# START-001: what clinicians are saying

> 66 statements from 20 sources (3 videos, 15 posts, 2 papers), 40 of them from 5 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026.

## Report

- Trial: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)
- NCT ID: NCT05592626
- Registry: https://clinicaltrials.gov/study/NCT05592626
- Sponsor: Marengo Therapeutics, Inc.
- Phase: Phase 1/Phase 2
- Status: Recruiting
- Drugs tested: invikafusp alfa (STAR0602); invikafusp alfa (STAR0602) plus irinotecan; invikafusp alfa (STAR0602) plus docetaxel
- Indication: antigen-rich advanced solid tumors
- Version: v1.0.0, edition 1
- Accepted: 2026-11-19 UTC
- Last checked: 2026-11-19 UTC
- Release hash: e2024c46f4598f6ec53a03ed10612732e9b12ba4349af392bdfaf5bcb0537c28

## Counts

- Commentary sources screened: 52
- Sources cited by verified statements: 20
- Verified statements: 66
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 40
- Findings: 7
- Named people in screened sources (unnamed speakers and accounts not counted): 13
- Speakers cited: 13
- Cited speakers with a verified identity: 8
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 5
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 5
- By role and specialty (the abstract's specialty counts):
  - 3 physician, specialty not confirmed
  - 1 physician, Gastroenterology
  - 1 physician, Medical oncology
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A physician reads START-001 favorably because of activity after checkpoint-inhibitor failure, but stresses that the evidence is preliminary. A speaker's stronger endorsement concerns TMB-high colorectal cancer without liver metastases; another cautions against treating activity as established benefit, citing small numbers. Cytokine-release syndrome remains a concern in the discussion. Durability is unresolved, and results from different dose and biomarker groups cannot be treated as a single response estimate.

## Findings (titles)

- F1. START-001: what most speakers highlight in preliminary activity in refractory tumors
  - 22 statements from 9 speakers in 15 sources, 3 of them podcasts or videos.
  - 8 of the 9 named speakers in this finding hold this view.
  - 4 of the report's 5 cited clinicians.
- F2. Early transient AEs: what some clinicians highlight, but some speakers flag CRS risk
  - 7 statements from 5 speakers in 7 sources, 1 of them a podcast or video.
  - 2 of the 5 named speakers in this finding hold this view, each a confirmed clinician; 2 of the 5 hold its caveat, “some speakers flag CRS risk”.
  - 3 of the report's 5 cited clinicians.
- F3. Trial access: what speakers say
  - 6 statements from 4 speakers in 6 sources.
  - 2 of the report's 5 cited clinicians.
- F4. Immune-cold tumors: what speakers say
  - 8 statements from 4 speakers in 6 sources, 1 of them a podcast or video.
  - 4 of the report's 5 cited clinicians.
- F5. T-cell selectivity: what speakers stress; a clinician ties RP2D to expansion
  - 11 statements from 4 speakers in 6 sources, 1 of them a podcast or video.
  - 4 of the 4 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician ties RP2D to expansion”.
  - 3 of the report's 5 cited clinicians.
- F6. Invikafusp alfa: why a speaker favors it on a hunch and a scan example
  - 5 statements from 2 speakers in 1 source.
  - 1 of the 2 named speakers in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F7. Preclinical T-cell reprogramming: why a clinician supports clinical testing
  - 15 statements from 2 speakers in 3 sources.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician.
  - 2 of the report's 5 cited clinicians.

1 of the 7 findings and 15 of the 66 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 22 | 20 | 15 | 9 | 4 |
| F2 | 7 | 7 | 7 | 5 | 4 |
| F3 | 6 | 8 | 6 | 4 | 3 |
| F4 | 8 | 9 | 6 | 4 | 3 |
| F5 | 11 | 13 | 6 | 4 | 3 |
| F6 | 5 | 3 | 1 | 2 | 3 |
| F7 | 15 | 19 | 3 | 2 | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 16 | 1 | 0 | 0 | 5 | 25 | 1 | 10 posts and articles, 3 podcasts and video, 2 publications |
| F2 | 5 | 0 | 0 | 0 | 2 | 7 | 0 | 4 posts and articles, 1 podcast or video, 2 publications |
| F3 | 4 | 1 | 1 | 0 | 0 | 8 | 0 | 6 posts and articles |
| F4 | 3 | 2 | 0 | 0 | 3 | 9 | 0 | 3 posts and articles, 1 podcast or video, 2 publications |
| F5 | 4 | 0 | 0 | 1 | 6 | 15 | 0 | 3 posts and articles, 1 podcast or video, 2 publications |
| F6 | 1 | 0 | 1 | 2 | 1 | 5 | 0 | 1 post or article |
| F7 | 7 | 0 | 0 | 7 | 1 | 19 | 0 | 3 posts and articles |

### Trial dimensions

- Primary endpoint: Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1: F5 (1 shared claims)
- Primary endpoint: Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs): F1 (2 shared claims), F2 (5 shared claims)
- Primary endpoint: Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR): F1 (15 shared claims), F2 (2 shared claims), F4 (1 shared claims)
- Secondary endpoints: F1 (7 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (1 shared claims), F6 (1 shared claims)
- Population and setting: F1 (12 shared claims), F2 (1 shared claims), F4 (3 shared claims), F5 (1 shared claims)
- The comparison: F3 (1 shared claims), F5 (2 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (5 shared claims)
- Design and conduct: no finding draws on it directly

## Abbreviations

- AE: adverse event
- CRS: cytokine release syndrome
- DLT: dose-limiting toxicity
- FDA: US Food and Drug Administration
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- ORR: objective response rate
- RP2D: recommended phase 2 dose
- SAE: serious adverse event

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 66 | Paid |
| Who said each statement: the cited speakers | 13 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 5 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 8 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 13 | Free |
| Sources with links | 20 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 5 of the 13 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

12 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1 | discussed | 1 | 1 |
| Primary endpoint: Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | discussed | 5 | 5 |
| Primary endpoint: Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR) | discussed | 15 | 12 |
| Secondary endpoints | discussed | 8 | 6 |
| Population and setting | discussed | 13 | 10 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 2 | 2 |
| Safety and tolerability | discussed | 5 | 5 |
| Design and conduct | no commentary found | 0 | 0 |
| Selective signaling and biological dose selection | discussed | 8 | 4 |
| Baseline predictors and treatment-induced immune changes | discussed | 6 | 4 |
| Research access, patient support and regulatory expectations | discussed | 6 | 5 |
| Anecdotal comparison with Anktiva in metastatic disease | discussed | 5 | 1 |
| Preclinical rationale and proposed immune reprogramming | discussed | 15 | 3 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 10 statements · 15%** | | | |
| YouTube | 10 | 3 | 3 |
| **Posts · 48 statements · 73%** | | | |
| X threads | 48 | 15 | 46 |
| LinkedIn posts | 0 | 0 | 2 |
| Bluesky threads | 0 | 0 | 1 |
| **Primary sources · 8 statements · 12%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 8 | 2 | not screened |

- Screened window: 2022-10-28 to 2026-10-31
- Cited window: 2022-11-10 to 2026-10-31
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)
- Registry: NCT05592626 (https://clinicaltrials.gov/study/NCT05592626)
- Study IDs: CP-START-001 · 2023-505334-10-01
- Sponsor: Marengo Therapeutics, Inc.
- Design: Phase 1/Phase 2 · interventional, non randomized, sequential, phase1, phase2
- Status: Recruiting
- Enrollment: 366 (estimated)
- Start: 2023-01-04 (actual)
- Primary completion: 2027-09 (estimated)
- Primary endpoint: Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1 (Cycle 1 (Cycle length= 28 days))
- Primary endpoint: Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) (Up to 3 years)
- Primary endpoint: Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR) (Up to 3 years)
- Intervention: STAR0602 (drug)
- Intervention: Irinotecan (Camptosar) (combination product)
- Intervention: Docetaxel (Taxotere) (combination product)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 33 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 25 sources about other trials or topics are not included.
- Repeated posts, reposts, presentation summaries and near-identical interview extracts should not be counted as independent HCP assessments.
- Several favorable views come from people described by their sources as involved in START-001 or STAR0602 development; those descriptions do not establish independent external endorsement.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The accounts use different phases, dose subsets, biomarker groups and outcome definitions. Percentages cannot be pooled, and target-lesion regression must not be relabeled as objective response or disease control.
- Small patient numbers and uncertain durability limit the strength of the clinical-benefit interpretation, even where speakers are enthusiastic.
- No trial protocol or matching regulatory label was available in the reviewed material. Detailed supportive-care rules and the X exchange's FDA-approval assertion could not be independently checked.
- The access and referral statements are dated experiences, not confirmation of current site availability or individual eligibility. A speaker's cancer type is not stated.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-19 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-19 UTC. No changes.

## Offer

- Size: Focused · 66 verified statements · 40 from 5 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (8 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/start-001-nct05592626
- Agents: POST https://www.erudio.com/api/orders with {"report": "start-001-nct05592626", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=start-001-nct05592626

## Cite

Erudio Health. START-001 (NCT05592626): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/start-001-nct05592626

## Questions

### How much does the START-001 report cost?

One edition costs $750 (Focused · 66 verified statements · 40 from 5 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the START-001 report cover?

66 statements from 20 sources (3 videos, 15 posts, 2 papers), 40 of them from 5 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the START-001 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "start-001-nct05592626" }) previews it and create_order({ "report": "start-001-nct05592626", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the START-001 report?

Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/start-001-nct05592626.json
- Markdown: https://www.erudio.com/reports/start-001-nct05592626.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/start-001-nct05592626/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "start-001-nct05592626"}`
